Inncardio, Inc. Commences Trading on OTCBB Under Ticker 'INDO'

Inncardio, Inc. Commences Trading on OTCBB Under Ticker 'INDO'



NEW YORK, March 4  /PRNewswire-FirstCall/ -- Inncardio, Inc. (OTC:INDO)
(BULLETIN BOARD: INDO) , a biotechnology company focused on the development of
treatments and therapies targeted at cardiovascular-related diseases, today
announced that it has been approved to trade on the OTC Bulletin Board(R)
(OTCBB) under the ticker symbol "INDO."

"Inncardio continues to seek additional early stage development products to
expand its portfolio of cardiovascular product candidates," commented Bernard
Ross, Chief Executive Officer of Inncardio. "The commencement of the company
trading on the OTCBB serves as an entry into the public markets and the
additional financial opportunities therein."

About Inncardio, Inc.

Inncardio, Inc., a subsidiary of Bioaccelerate Holdings Inc. (OTC:BACL)
(BULLETIN BOARD: BACL) , is a biotechnology company engaged in the acquisition,
development and commercialization of treatments and therapies targeted at
various cardiovascular diseases. The Company's management team is focused on
both the ongoing development of Inncardio's products to build value prior to
partnering and the in-licensing of additional cardiovascular products to
further enhance the Company's commercial value. The Company currently has six
compounds in its portfolio. Three of the compounds are currently undergoing
clinical investigation, and three are in pre-clinical studies. Inncardio's lead
clinical development product is being investigated for use as a post-stroke
therapy that has a novel delivery profile and is targeted to reduce the
incidence and severity of ischemic deficits in patients with subarachnoid
hemorrhage from rupture intracranial berry aneurysm.

About Bioaccelerate Inc.

Bioaccelerate Holdings Inc. (BACL.OB) is a pharmaceutical development
organization ("PDO") that seeks to acquire, develop and commercialize novel
pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate
uses its broad network of academic, industry and capital market relationships
to expedite drug development and raise capital to create and fund its
subsidiary companies, which are organized by vertical portfolios in five
therapeutic areas: oncology, specialty pharmaceuticals, central nervous system
disorders (CNS), cardiovascular disease and anti-infectives.

Bioaccelerate conducts its business directly and through its subsidiaries. The
company holds majority equity interests in 10 biopharmaceutical companies,
three of which are public, and holds minority interests in four
biopharmaceutical companies, two of which are public. The company also holds a
minority equity interest in a public nanotechnology company. Bioaccelerate's
strategy relies on its development network for research, clinical development
and project management to guide early-stage compounds from the discovery
process through to Phase II/III development where incremental value can be
created. Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin
Board under the symbol "BACL.OB." For more information on Bioaccelerate, visit
the company's website at http://www.bioaccelerate.com/.

Safe Harbor

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to: risks associated with pre-clinical and
clinical developments in the biopharmaceutical industry in general and in
Inncardio or Bioaccelerate's compounds under development in particular; the
potential failure of Inncardio or Bioaccelerate's compounds under development
to prove safe and effective for treatment of disease; uncertainties inherent in
the early stage of Inncardio or Bioaccelerate's compounds under development;
failure to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or strategic
initiatives that change Inncardio or Bioaccelerate's business, structure or
projections; the development of competing products; uncertainties related to
Inncardio or Bioaccelerate's dependence on third parties and partners; and
those risks described in the filings with the SEC, all of which are under
Bioaccelerate's prior name Mobile Design Concepts, Inc. and Inncardio's prior
name Softwall Equipment Corp. Inncardio and Bioaccelerate disclaim any
obligation to update these forward-looking statements.

   Contacts:

   Bioaccelerate Holdings Inc.
   Christopher O'Toole
   Senior Vice President
   212-897-6849

   Inncardio Inc.
   Bernard Ross
   Chief Executive Officer
   [phone]

   Matthew Haines (Investors)
   Vice President
   Noonan Russo
   212-845-4235

   Emily Poe (Media)
   Vice President
   Noonan Russo
   212-845-4266


DATASOURCE: Bioaccelerate Holdings Inc.; Inncardio Inc.



CONTACT:  Christopher O'Toole, Senior Vice President of Bioaccelerate

Holdings Inc., [phone]; or Bernard Ross, Chief Executive Officer of

Inncardio Inc., [phone]; or Matthew Haines (Investors), Vice

President, [phone], or Emily Poe (Media), Vice President,

[phone], both of Noonan Russo 



Web site:  http://www.bioaccelerate.com/ 

Copyright